GSK’s Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer Read more
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 Read more
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases Read more
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care Read more
Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics Read more
Novartis Scemblix granted FDA Priority Review for the treatment of adults with newly diagnosed CML Read more
Bayer announces positive topline results for NUBEQA (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) Read more
Merck Begins Commercial Production of First GMP-Compliant Manufacturing Line for Cell Culture Media in China Read more